Objective: To evaluate the safety of dapagliflozin for Type 2 Diabetes Mellitus (T2DM). Methods: A systematic search of Pubmed, Embase, Cochrance Library, Web of Science, CNKI, Wanfang Data and VIP database for randomized controlled trials (RCTs) comparing dapagliflozin with placebo was performed up to February 2018. The index words included dapagliflozin, type 2 diabetes mellitus and randomized controlled trial. Results: A total of 19 RCTs involving 7704 participants were incorporated into the study. Compared with placebo, dapagliflozin did not increase the risk of hypoglycemia [OR = 1.14, 95%CI (0.95, 1.36), P = 0.17] and hypotension [OR = 1.43, 95%CI (0.94, 2.17), P = 0.10], but significantly increased the incidences of renal adverse events [OR = 1.57, 95%CI (1.17, 2.09), P = 0.002], genital tract infection [OR = 3.65, 95%CI (2.93, 4.56), P < 0.00001] and urinary tract infection [OR = 1.36, 95%CI (1.15, 1.61), P = 0.0004] and related doses. Conclusions: Generally, dapagliflozin had no risk of hypoglycemia and hypotension in patients with T2DM, but there were risks of renal adverse events and urogenital tract infection. Due to the limitations of this study, larger samples and RCTs with long-term follow-up are needed for further verification.
Introduction
As a common disease in China, the incidence of T2DM has been increasing year by year, and drug therapy is the main method of treatment. Sodium glucose co-transporter 2 (SGLT-2), as the most important glucose transporter in the kidney, is responsible for the reabsorption of 90% glucose in the kidney [1] . The DOI: 10.4236/ym.2018. 23014 130 Yangtze Medicine SGLT-2 inhibitor, dapagliflozin is a novel oral hypoglycemic drug for the treatment of T2DM, which is independent from islet β-cell function and insulin sensitivity. It functions by increasing renal clearance of glucose, attenuating renal reabsorption of glucose and excreting excess glucose from the urine, thereby reducing blood glucose [2] . Studies have shown that dapagliflozin has multiple benefits such as reduction in blood glucose, weight and blood pressure. However, there is also risk for urogenital tract infections [3] . In this study, the safety is further analyzed by retrieving RCTs of dapagliflozin versus placebo through meta-analysis. 
Data and Methods

Criteria for Inclusion and Exclusion of Literature
Evaluation Index
Safety related indicators: hypoglycemia events, hypotension events, adverse renal reactions, genital tract infections, urinary tract infections.
Search Strategy
The search strategy follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [4] . 
Data Extraction
Data were independently abstracted by the two principal reviewers and any discrepancies were resolved by consensus. The data extracted included title, author, and year of publication, country, intervention measures, sample size, patient age, treatment time, main outcome indicators and intentionality analysis.
Quality Assessment
Jadad scoring criteria were used [5] , including 4 items: random method, assignment concealment, blind method and withdrawal. The RCT score was 1 -7, 1 -3 as low quality and 4 -7 as high quality.
Data Analysis
Outcomes were pooled using Review Manager 5.3 software. Dichotomous data were presented as odds ratio (OR) or risk ratio (RR). All results were estimated from each study with 95% confidence intervals (CIs). Heterogeneity was assessed using the I 2 statistic. If P > 0.1, I 2 < 50%, a fixed-effect model with the Mantel-Haenszel method was used; otherwise, the random-effect model was adopted.
Subgroup analysis was performed according to the different doses of dapagliflozin (1 mg, 2.5 mg, 5 mg, 10 mg and 20 mg). Funnel plot was adopted to evaluate the publication bias. The bilaterally symmetric graph indicates a low risk of publication bias. Otherwise, the risk of publication bias may exist.
Results
The Basic Characteristics and Process of Inclusion Study
A total of 19 RCTs involving 7704 participants was incorporated into the study, including 5304 cases of dapagliflozin group and 2400 cases of the placebo group.
All 19 RCTs were performed from 2009 to 2016, and the follow-up duration was ≥12 weeks. Baseline data for both groups were described in all trials, and there was no statistical difference in general between the dapagliflozin and placebo groups before treatment (P > 0.05). The screening process is displayed in Figure   1 . The basic information contained in the study is shown in Table 1 . 
Risk Assessment of Bias Included in the Study
Two reviewers independently applied the Cochrane Risk of Bias tool to assess the risk of bias in the RCTs. The following methodological features relevant to the minimization of bias were assessed: randomization, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. The following judgments were used: low risk, high risk, or unclear risk (either lack of information or uncertainty regarding the potential for bias). The bias risk assessment is shown in Figure 2 .
Results of Meta-Analysis
Hypoglycemia Event
A total of 19 studies were implemented [3] [6]- [23] to compare hypoglycemia events. Heterogeneity was detected in study subgroups (2.5 mg, 5 mg, 10 mg, 20 mg), indicating that there was no statistically significant heterogeneity (I 2 = 0%, P = 0.96), (I 2 = 0%, P = 0.67), (I 2 = 0%, P = 0.70), (I 2 = 0%, P = 0.89) between studies included in the analysis (Figure 3) . Therefore, the M-H fixation effect model was used for meta-analysis. Funnel plot of publication bias evaluation is presented in Figure 4 . There was no risk of publication bias among subgroups in the study. No significant differences were observed in the comparison results of dapagliflozin with placebo in the incidence of hypoglycemia event [OR = 1.14, 95%CI (0.95, 1.36), P = 0.17], as shown in Figure 3 . to compare hypotension events. Heterogeneity was detected in the study subgroups (2.5 mg, 5 mg, 10 mg), indicating that there was no statistically significant heterogeneity (I 2 = 0%, P = 0.60), (I 2 = 0%, P = 0.85), (I 2 = 0%, P = 0.79) between studies included in the analysis ( Figure 5) . Therefore, the M-H fixation to compare renal adverse events. Heterogeneity was detected in study subgroups (2.5 mg, 5 mg, 10 mg), indicating that there was no statistically significant heterogeneity (I 2 = 0%, P = 0.42), (I 2 = 0%, P = 0.85), (I 2 = 0%, P = 0.89) between studies included in the analysis (Figure 7) . Therefore, the M-H fixation effect model was used for meta-analysis. Funnel plot of publication bias evaluation is presented in Figure 8 . 
Hypotension Event
Renal Adverse Event
Genital Tract Infections
A total of 19 studies were implemented [3] [6]- [23] to compare genital tract infections. Heterogeneity was detected in the study subgroups (2.5 mg, 5 mg, 10 mg, 20 mg), indicating that there was no statistically significant heterogeneity (I 2 = 0%, P = 0.81), (I 2 = 0%, P = 0.98), (I 2 = 0%, P = 0.64), (I 2 = 0%, P = 0.82) between studies included in the analysis (Figure 9 ). Therefore, the M-H fixation effect model was used for meta-analysis. Funnel plot of publication bias evaluation is presented in Figure 10 . There was no risk of publication bias among 
Urinary Tract Infections
A total of 19 studies were included [3] [6]- [23] to compare urinary tract infec- 
Discussion
The meta-analysis suggests that dapagliflozin had no difference in the risk of hypoglycemia and hypotension events compared with placebo, and was safer than sulfonylurea, insulin and other hypoglycemic agents with a higher risk of hypoglycemia. Studies have illustrated that Chinese adults with type 2 diabetes were more complicated due to hypertension and other cardiovascular risk factors [24] . Dapagliflozin can reduce blood glucose while reducing blood pressure and weight [25] [26], improve oxidative stress and endothelial function and reduce arteriosclerosis [27] [28], with potential cardiovascular benefits [29] . Multiple studies on the effects of renal function proved that the eGFR and urinary albumin-creatinine ratio were not significantly changed in the dapagliflozin 
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